AB009. Regenerative therapy in neonates with hypoxic ischemic encephalopathy

AB009. Regenerative therapy in neonates with hypoxic ischemic encephalopathy

Haruo Shintaku1, Makoto Nabetani2, Takashi Hamazaki1, Satoshi Ohnishi1, Emi Tanaka1, Satoshi Kusuda3, Masanori Tamura4, Sinichi Watabe5, Masahiro Hayakawa6, Yoshiaki Sato6, Masahiro Tsuji7, Akihiko Taguchi8, Hiroyuki Ichiba9, Akira Oka10, Rintaro Mori11, Takeo Mukai10, Tokiko Nagamura-Inoue10

1Osaka City University Graduate School of Medicine, Osaka, Japan; 2Yodogawa Christian Hospital, Osaka, Japan; 3Kyorin University, Tokyo, Japan; 4Saitama University, Saitama, Japan; 5Kurashiki Central Hospital, Kurashiki, Japan; 6Nagoya University, Nagoya, Japan; 7Kyoto Women’s University, Kyoto, Japan; 8Institute of Biomedical Research and Innovation, Kobe, Japan; 9Osaka City General Hospital, Osaka, Japan; 10The Tokyo University, Kyoto, Japan; 11National Center for Child Health and Development, Tokyo, Japan

Abstract: Hypoxic ischemic encephalopathy (HIE) is considered to be a major cause of cerebral palsy (CP) in neonates with moderate or severe asphyxia. To date, therapeutic hypothermia (TH) has been the only effective treatment for HIE to prevent the development of CP. However, even if infants are treated with hypothermia, nearly half of them die or left with moderate to severe neurological impairments as yet. A recent publication in the United States, indicated benefits of autologous umbilical cord blood stem cell transplantation combined with TH for HIE, drawing attention to cell therapy for perinatal brain injury. Regenerative medicine by umbilical cord blood stem cells (UC-BSCs) or UC mesenchymal stromal cells (UC-MSCs) which combines the action of suppressing early inflammation and the action of promoting regeneration is expected as a remarkable excellent therapeutic method as a treatment for HIE. UCBSCs was collected aseptically and prepared by using SEPAX which need more than 40ml of UC blood. UC-MSCs were collected aseptically and isolated from UC, and cryopreserved after culture. Infants admitted to the NICU of 6 hospitals in our research group will be eligible if they are ≥36 weeks’ gestational age and birth weight ≥1,800 g with HIE and meet the cooling criteria. UCBSCs therapy for neonatal HIE in addition to TH was performed in 6 newborn patients. All of them have discharged NICU without support of ventilator and survived from 9 months to 3 years. UC-MSCs have been defined and characterized as follows: (I) abundant sources and ease of collection, storage, and transport; (II) low immunogenicity with significant immunosuppressive ability. Autologous UCBSCs for newborn HIE is safe and feasible, and warrants a larger and controlled phase II study. UC-MSCs therapy will give the possibility of treatment to patients who could not get UC blood.

Keywords: Regenerative therapy; hypoxic ischemic encephalopathy; cord blood stem cells; umbilical cord derived stem cells

doi: 10.21037/pm.2018.AB009
Cite this article as: Shintaku H, Nabetani M, Hamazaki T, Ohnishi S, Tanaka E, Kusuda S, Tamura M, Watabe S, Hayakawa M, Sato Y, Tsuji M, Taguchi A, Ichiba H, Oka A, Mori R, Mukai T, Nagamura-Inoue T. Regenerative therapy in neonates with hypoxic ischemic encephalopathy. Pediatr Med 2018;1:AB009.